UBS Group
PMCB icon

UBS Group’s PharmaCyte Biotech PMCB Stock Holding History

UBS Group’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$12 Sell
2
-216
-99% -$2.26K ﹤0.01% 11053
2026
Q2 		$3.19K Sell
218
-20
-8% -$286 ﹤0.01% 9225
2026
Q1 		$3K Buy
238
+93
+64% +$1.35K ﹤0.01% 9160
2025
Q4 		$1.99K Buy
145
+75
+107% +$1.28K ﹤0.01% 9414
2025
Q3 		$1.28K Sell
70
-1,119
-94% -$21.2K ﹤0.01% 9385
2025
Q2 		$24.6K Buy
1,189
+562
+90% +$11.9K ﹤0.01% 8304
2025
Q1 		$14.9K Buy
627
+528
+533% +$16.3K ﹤0.01% 8407
2024
Q4 		$2.94K Sell
99
-341
-78% -$11.2K ﹤0.01% 8960
2024
Q3 		$16K Sell
440
-1,011
-70% -$35.8K ﹤0.01% 7493
2024
Q2 		$54K Buy
+1,451
New +$59.4K ﹤0.01% 6633
2024
Q1 		– Sell
-1
Closed -$41 – 9031
2023
Q4 		$29 Buy
+1
New +$41 ﹤0.01% 9047
2023
Q3 		– Hold
0
– – – 9128
2023
Q2 		– Sell
-89
Closed -$5.07K – 8670
2023
Q1 		$4.91K Buy
+89
New +$4.97K ﹤0.01% 8122
2022
Q4 		– Hold
0
– – – 10535
2022
Q3 		– Hold
0
– – – 10787
2022
Q2 		– Sell
-307
Closed -$12.7K – 10779
2022
Q1 		$13K Buy
307
+114
+59% +$4.81K ﹤0.01% 8068
2021
Q4 		$9K Buy
193
+14
+8% +$733 ﹤0.01% 8920
2021
Q3 		$11K Buy
+179
New +$12K ﹤0.01% 7901

Other funds holding PMCB

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
StoneX Group
StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Equitec Proprietary Markets
Equitec Proprietary Markets Chicago, Illinois $400M AUM 66.98% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $43.4M AUM 20.78% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return

UBS Group's PMCB Position: Q3 2026 in Review

UBS Group reduced its PharmaCyte Biotech (PMCB) stake by 99% in Q3 2026, selling an estimated $2.26K and leaving 2 shares worth $12. The position accounts for ﹤0.01% of the portfolio, ranked #11053.

UBS Group first reported a position in PMCB in Q3 2021 and has held it in 15 quarters since. The position peaked at $54K in Q2 2024. 13 funds tracked by Wall St. Rank hold PMCB as of Q3 2026.

  • UBS Group held 2 shares of PharmaCyte Biotech worth $12 as of Q3 2026.
  • UBS Group sold 216 PharmaCyte Biotech shares in Q3 2026, an estimated $2.26K.
  • PharmaCyte Biotech made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #11053 holding.
  • UBS Group first reported a position in PharmaCyte Biotech in Q3 2021 and has held it in 15 quarters since.
  • UBS Group's PharmaCyte Biotech position peaked at $54K in Q2 2024.
  • 13 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.